Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Vietnam Plasma Fractionation Market by Product (Albumin, Immunoglobulins, Coagulation Factor VIII, and Coagulation Factor IX), Application (Neurology, Hematology, Immunology, Critical Care, and Others), and End User (Hospitals and Research Laboratories): Opportunity Analysis and Industry Forecast, 2020–2027

A06438
Pages: 108
Jun 2020 | 421 Views
 
Author(s) : Trupti Wadekar, Snehal Manjrekar , Onkar Sumant
Tables: 36
Charts: 27
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Vietnam Plasma Fractionation Market

Request Now !

The Vietnam plasma fractionation market was valued at $56.62 million in 2019, and is expected to reach $79.03 million by 2027, registering a CAGR of 5.3% from 2020 to 2027. Plasma is a vital biological element of blood, which is used as a treatment for a number of medical disorders. Proteins present in plasma are mostly antibodies, coagulation factors, albumin, fibrinogen, and globulins. Each of these proteins can be separated and extracted using different fractionation techniques that produce varied plasma products for treating a diverse portfolio of diseases. Some plasma derivatives obtained from fractionation process are fibrin glue, factor VIII, factor IX, fibrinogen, fraction V, albumin, protein C, and factor XI. These plasma derivatives have major applications in fields of neurology, hematology, immunology, and critical care. In addition, these products find their use in rheumatology, pediatrics, and dermatology. For instance, plasma derivatives such as coagulation factor VIII are used in treating blood related disorders such as hemophilia; and immunoglobulins (IVIG) are used in the treatment of neurological conditions and primary immunodeficiency disorders. Likewise, albumin is one of the key proteins used in the treatment of Alzheimer’s, renal dialysis, sepsis, and sealant in surgeries, medical devices coatings, drug formulation agent, and as a vaccine ingredient. Owing to the wide range of applications in several diseases, the demand for plasma fractionation products is estimated to increase in the future.

Vietnam Plasma Fractionation Market

Get more information on this report : Request Sample Pages

Vietnam had a population of approximately 94 million as of 2019. The country had a large pool of population suffering from Parkinson’s disease, brain cancer, epilepsy, hemophilia, and autoimmune disorders, owing to the use of Agent Orange herbicide during the Vietnam War. In addition, the country is expectedto become an aged society by 2035, as per data published by the World Bank Group in 2020. The aged population in the country is more vulnerable to severe medical conditions that may involve use of plasma fractionated products. Thus, this predictable change in demographics is projected to surge the onset of different diseases among the Vietnamese population in the future, thereby, resulting in increased demand for novel and innovative plasma therapies. Subsequently, the country provides profitable opportunities to pharmaceutical companies for setting up their plasma fractionation plants to meet the population demand.

Surge in aged population in the country that are vulnerable to serious illnesses along with pre-existing medical disorders are projected to drive the plasma fractionation market in Vietnam. Likewise, rise in use of plasma derivatives across wide-ranging areas of medicine and developing plasma collection centers are expected to drive the growth of the Vietnam plasma fractionation market. On the contrary, stricter regulations for both, high quality standards of plasma derivatives and logistics to source and collect blood plasma along with timely delivery are anticipated to hamper the market growth. However, initiatives such as “Make in Vietnam”, mobile healthcare initiatives, and Vietnam Medi-Pharm Expo are attracting several foreign direct investments and integration of technologically advanced medical services in the country’s healthcare sector for improving quality of life of people. These initiatives create ample opportunities for pharmaceutical companies to provide plasma fractionated products in Vietnam.

The Vietnam plasma fractionation market is segmented on the basis of product, application, and end user. By product, the market is classified into albumin, immunoglobulins, coagulation factor VIII, and Coagulation factor IX. By application, it is categorized into neurology, hematology, immunology, critical care, and others. By end user, it is bifurcated into hospitals and clinical research laboratories.

Product Segment Review

By product, the market is classified into albumin, immunoglobulins, coagulation factor VIII, and Coagulation factor IX. Under immunoglobulin segment, the Vietnam plasma fractionation market is further bifurcated in to Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG).The immunoglobulin segment is expected to dominate the Vietnam plasma fractionation market throughout the forecast period, owing to diversified use in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases.

Vietnam Plasma Fractionation Market
By Product

Your browser does not support the canvas element.

Immunoglobulins segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application Segment Review

By application, the neurology segment acquired the largest share of the Vietnam plasma fractionation market in 2019, and it is expected to bethe fastest growing segment during the forecast period. This is attributable to the surge in neurological disorders that involve use of plasma fractionated products for treatment. Prevalence of hydrocephalus, Parkinson’s disease, epilepsy, traumatic brain injuries, and cerebrovascular diseases particularly in non-urban communities, owing to lack of resources in the country drive the growth of the market for the neurology segment.

Vietnam Plasma Fractionation Market
By Application

Your browser does not support the canvas element.

Neurology segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

End User Segment Review

By end user, the hospital segment was the major contributor to the market in 2019, and is also expected to register fastest growth during the forecast period, owing to rise in number of hospitals in the country. Furthermore, plasma derivatives are employed in medical fields such as critical care and hematology. Treatments for these medical conditions areperformed by skilled professional in hospitals, thereby boosting the growth of the market for the end user segment.

Vietnam Plasma Fractionation Market
By End User

Your browser does not support the canvas element.

Hospitals segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits for Stakeholders:

  • This report provides a detailed quantitative analysis of the current Vietnam plasma fractionation market trends and forecast estimations from 2020to 2027, which assists to identify the prevailing market opportunities. 
  • An in-depth Vietnam plasma fractionation market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from2020 to 2027, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the Vietnam plasma fractionation market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of themarket.

Key Market Segments:

By Product

  • Albumin 
  • Immunoglobulins
    • Subcutaneous Immunoglobulin (SCIG)
    • Intravenous Immunoglobulin (IVIG)
  • Coagulation Factor VIII
  • Coagulation Factor IX

By Application

  • Neurology
  • Hematology 
  • Immunology 
  • Critical Care
  • Others

By End User 

  • Hospitals 
  • Clinical Research Laboratories
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Market overview

2.1.1. Market segmentation

2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Thereat of new entrants
3.3.4. Threat of substitutes
3.3.5. Intensity of competitive rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Pre-existing medical conditions in Vietnam
3.4.1.2. Unavailability of substitutes

3.4.2. Restraint

3.4.2.1. Stringent Regulations

3.4.3. Opportunity

3.4.3.1. Unmet needs of Vietnamese Population

3.5. COVID-19 Impact Analysis

CHAPTER 4: PLASMA FRACTIONATION MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast

4.3. Immunoglobulins

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast

4.3.2.1. Subcutaneous Immunoglobulin

4.3.2.1.1. Market size and forecast

4.3.2.2. Intravenous Immunoglobulin

4.3.2.2.1. Market size and forecast

4.4. Coagulation factor VIII

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast

4.5. Coagulation factor IX

4.5.1. Market size and forecast

CHAPTER 5: PLASMA FRACTIONATION MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Neurology

5.2.1. Market size and forecast

5.3. Hematology

5.3.1. Market size and forecast

5.4. Immunology

5.4.1. Market size and forecast

5.5. Critical care

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

CHAPTER 6: PLASMA FRACTIONATION MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast

6.3. Clinical research laboratories

6.3.1. Market size and forecast

CHAPTER 7: COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. BIOTEST AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BIO PRODUCTS LABORATORY LTD.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio

7.4. GETZ HEALTHCARE

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. GRIFOLS SA

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. KEDRION BIOPHARMA

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. OCTAPHARMA

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. NOVO NORDISK

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. SANOVA HEALTHCARE

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio

7.10. SANQUIN BLOOD SUPPLY FOUNDATION

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

7.11. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.11.5. Business performance
7.11.6. Key strategic moves and developments

LIST OF TABLES

TABLE 01. DISEASES RELATED TO AGENT ORANGE
TABLE 02. VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 03. VIETNAM PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 04. VIETNAM PLASMA FRACTIONATION MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 05. BAXTER: COMPANY SNAPSHOT
TABLE 06. BAXTER: PRODUCT SEGMENTS
TABLE 07. BAXTER: PRODUCT PORTFOLIO
TABLE 08. BIOTEST AG: COMPANY SNAPSHOT
TABLE 09. BIOTEST AG: OPERATING SEGMENTS
TABLE 10. BIOTEST AG: PRODUCT PORTFOLIO
TABLE 11. BIO PRODUCTS LABORATORY LTD.: COMPANY SNAPSHOT
TABLE 12. BIO PRODUCTS LABORATORY LTD.: OPERATING SEGMENTS
TABLE 13. BIO PRODUCTS LABORATORY LTD.: PRODUCT PORTFOLIO
TABLE 14. GETZ HEALTHCARE: COMPANY SNAPSHOT
TABLE 15. GETZ HEALTHCARE: OPERATING SEGMENTS
TABLE 16. GETZ HEALTHCARE: PRODUCT PORTFOLIO
TABLE 17. GRIFOLS SA: COMPANY SNAPSHOT
TABLE 18. GRIFOLS SA: OPERATING SEGMENTS
TABLE 19. GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 20. KEDRION: COMPANY SNAPSHOT
TABLE 21. KEDRION: OPERATING SEGMENTS
TABLE 22. KEDRION: PRODUCT PORTFOLIO
TABLE 23. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 24. OCTAPHARMA: OPERATING SEGMENTS
TABLE 25. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 26. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 27. NOVO NORDISK: OPERATING SEGMENTS
TABLE 28. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 29. SANOVA HEALTHCARE: COMPANY SNAPSHOT
TABLE 30. SANOVA HEALTHCARE: OPERATING SEGMENTS
TABLE 31. SANOVA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 32. SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 33. SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 34. SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 35. TAKEDA: COMPANY SNAPSHOT
TABLE 36. TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. VIETNAM PLASMA FRACTIONATION MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE COMPETITIVE RIVALRY
FIGURE 08. PERCENTAGE OF AGING POPULATION IN VIETNAM (AGED 65 AND OVER) 2015–2018
FIGURE 09. BAXTER: NET SALES, 2017–2019 ($MILLION)
FIGURE 10. BAXTER: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 11. BAXTER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 12. BIOTEST AG: NET SALES, 2017–2019 ($MILLION)
FIGURE 13. BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 14. BIOTEST AG: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 15. GRIFOLS SA: NET SALES, 2017–2019 ($MILLION)
FIGURE 16. GRIFOLS SA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 17. GRIFOLS SA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 18. KEDRION: NET SALES, 2017–2019 ($MILLION)
FIGURE 19. KEDRION: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20. NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 21. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22. NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23. SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2017–2018 ($MILLION)
FIGURE 24. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 26. TAKEDA: NET SALES, 2018–2020 ($MILLION),
FIGURE 27. TAKEDA: REVENUE SHARE, BY REGION, 2020 (%)

 
 

The plasma fractionation products are expected to witness high adoption in the near future, owing to increase in applications of these products to treat varied range of diseases. The market is exhibiting high growth rate, owing to surge in awareness about use of the plasma fractionation products in various medical aspects.

Moreover, surge in geriatric population across Vietnam, which is predisposed to rare diseases that require plasma products for treatment also fuels the growth of the market. Factors, such as improvement in healthcare facilities, rise in disposable income, and rapidly evolving economic conditions are awaited to offer beneficial opportunities for the growth of the Vietnam plasma fractionation market. However, stricter regulations hinder the growth of the market.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of Vietnam Plasma Fractionation Market is $79.03 Million

A. The forecast period in the report is from 2020 to 2027

A. The market value of Vietnam Plasma Fractionation Market in 2019 was $52.21 Million

A. The base year for the report is 2019

A. Yes, Vietnam Plasma Fractionation companies are profiled in the report

A. The top companies that hold the market share in Vietnam Plasma Fractionation Market are Baxter International Inc., Bio Product Laboratory, Biotest AG, Csl ltd., Grifols SA, and Kedrion.

A. No, there is no value chain analysis provided in the Vietnam Plasma Fractionation Market report

A. The key trends in the Vietnam Plasma Fractionation Market are prevailing diseased conditions in the population coupled with the growth in geriatric individuals vulnerable to many diseases.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Vietnam Plasma Fractionation Market

  • Data Pack
  • $1,845
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $2,979
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $3,099
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $4,322
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts